2019 FLASCO Fall Session Highlights

The Florida Society of Clinical Oncology leadership enjoyed seeing you at our Fall Session, a 2 day meeting designed for medical oncologists, hematologists, radiation oncologists, surgical oncology, pathologists, oncology nurses, nurse practitioners, pharmacists, physician assistants, oncology administrators, residents, and fellows that manage heath care for cancer patients. This conference provided an emphasis on multidisciplinary collaboration among all professional health care teams with dynamic educational tracks that focused on specific driven topics addressing the current and future changes in the landscape of cancer care.

The 2019 Fall meeting centered on the multi-disciplinary presentations  and case studies in Colon Cancer and Multiple Myeloma which included the collaboration of top clinicians.  Additional sessions included information on hot topics in advance provider practitioners, pharmacy, and administration.




Thank you for supporting the 2019 FLASCO Fall Session!

 EXHIBIT INFO:  We are expecting 150-175 attendees at the FLASCO Fall Session.  Click here to view the 2019 Fall Session Attendee Roster.


21st Century

AbbVie Pharmaceuticals

Acrotech Biopharma

Adaptive biotechnologies

Advanced Accelerator Applications, a Novartis company

Agios Pharmaceuticals

Alexion Pharmaceuticals

AMAG Pharmaceuticals

Amgen Oncology

Array Biopharma

Astellas Pharma


Bayer Healthcare


Boehringer Ingelheim

Briova Rx

Bristol-Myers Squibb

Caris Life Sciences


Cleveland Clinic

Clovis Oncology

Coherus Biosciences

Daiichi Sankyo

Dova Pharmaceuticals

East Central Florida Cancer Control Collaborative


EMD Serono


EUSA Pharma


Florida Cancer Data System

Foundation Medicine


Genomic Health

Gilead Sciences

Guardant Health

Helsinn Therapeutics

IBM Watson Healthcare



Ipsen Biopharmaceuticals

Johnson & Johnson

Kite Pharma

Kroger Specialty Pharmacy

Lilly Oncology

McKesson Specialty Health


Moffitt Cancer Center

NanoString Technologies


New Century Health


Oncology Supply/ION Solutions

Pfizer Oncology


Puma Biotechnology

Rigel Pharmaceuticals

Roche Diagnostics

Rx Vantage

Sanofi Genzyme

Seattle Genetics


Sun Pharma

Surterra Wellness

Taiho Oncology

Takeda Oncology



Teva Pharmaceuticals

The Leukemia and Lymphoma Society

UF Health Cancer Center

Walgreens Specialty Pharmacy


Continuing Education

Accreditation and Credit Statements


Evaluation & Certificate of Attendance

  • A link to the evaluation survey will be emailed to you post-program. Please complete this within the allotted time frame. If you do not receive a post-program email by 11/15/19, reach out to the FLASCO office.
  • Your certificate of attendance will be emailed to you for download immediately after submission. Keep the certificate of attendance document for your files.


In support of improving patient care, the Medical Educator Consortium is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician: This activity has been approved for AMA PRA Category 1 Credit(s)TM.

Nurse/Advanced Nurse Practitioner: This activity has been approved for ANCC contact hours.

Pharmacist: This Application-based activity has been approved for ACPE contact hours.

Physician Assistant: NCCPA accepts AMA PRA Category 1 Credit(s)TM from organizations accredited by ACCME or a recognized state medical society.

Disclosure Policy – The Medical Educator Consortium (MEC) adheres to the Joint Accreditation Criteria and ACCME Standards for Commercial Support, which requires everyone in a position of controlling the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests related to the activity content.  MEC has implemented a mechanism to identify and resolve all conflicts of interest prior to the CME/CE activity being delivered to learners.  The source of all support from commercial interests will also be disclosed to learners prior to the beginning of the educational activity.  CME/CE activities must be balanced, independent of commercial bias, and designed to improve quality in health care. All recommendations involving clinical medicine must be based on evidence within the medical profession. 

Disclosure of Unlabeled Use – This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contradictions, and warnings.

Disclaimer – Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contradictions and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Poster Presentation

Abstracts for Poster Presentation

FLASCO Members Accepted Poster Abstracts

Ollie Anum, B.S., PharmD   

Review on CTL019 and KTEC19, CART-cell Agents used for the Treatment of Large B-cell Lymphoma                

Dharti Patel, Oak Hill Hospital

Mariya Fatakhova,Larkin University-College of Pharmacy

Mio Ezura, Nova Southeastern University

Nirali Vassa, Oak Hill Hospital

Ricardo Parrondo, MD, Mayo Clinic Florida


Accepted Industry Poster Abstracts 

Rama Blaraman, MD, Florida Cancer Affiliates, Bristol-Myers Squibb

Heather Copher-Sweeney, PharmD, Bristol-Myers Squibb

Trevor McKibbin, PharmD, Pfizer Oncology

Jennifer Sibley, Bristol-Myers Squibb

Jeff Steinberg, PharmD, Pfizer Oncology

Jessica Unzaga, PharmD, BCPS, Baptist Health South, Pfizer Oncology

Josean Vargas-Maisonet, PharmD

Nichole Allen & Yingtao Zhang, MD, Merck




Renaissance Orlando at SeaWorld 

6677 Sea Harbor Drive, Orlando, Florida






General Session Innovative Solutions and Best Practices in Clinical Research Howard “Skip” Burris III, MD, FACP, FASCO
General Session Breast Cancer Management: Emphasis on Immunotherapy Hope S. Rugo, MD


Multiple Myeloma and AL Amyloidosis

Case Study

Raymond Comenzo, MD

Emily Jonczak, MD


USP 800:

Beyond the Basics Part II Stronger Together

Lilit Smith, PharmD, MBA

Marie Anne Louis-Jeune, PharmD, BCPS

Pharmacy Updates in Immunotherapy & Rare Immunotherapy Toxicity Management: A case based approach Jennifer Swank, PharmD
APP/Nurse/Navigator Oncologic Emergencies Lisa Welsh, MBA, PA-C
APP/Nurse/Navigator Sexual Health in Oncology Maray Salina, MSN, RN, NP-C
Administrator Telemedicine Bill Manzie, MBA
Lunch Presentation The Benefits of Prescreening for Lung Cancer Luis E. Raez, MD, FACP, FOCP
Lunch Presentation Role of R2 in Previously Treated Follicular Lymphoma Celeste Bello, MD, MSPH
Lunch Presentation Using Huddles to Empower, Change, and Improve Employee Communication and Enhance Patient Care Carie Colby
Multidisciplinary Colon Cancer: A discussion regarding diagnosis and treatment for a patient under 50 Mintallah Haider, MD with Panel of Experts
Pharmacy Biosimilars: Beyond the Scientific Review Jorge Garcia, PharmD, MS, MHA, MBA, FACHE
Pharmacy Updates in Gastrointestinal Cancers Anand Shah, Pharmd, BCOP, BCPS
Pharmacy Navigating Your Way to Medication Assistance Program Success Susan Downey, PharmD c/o Angelica Berni, PharmD
APP/Nurse/Navigator USP 800: Beyond the Basics Lilit Smith, PharmD, MBA
APP/Nurse/Navigator Artificial Intelligence Mehool Patel, MD, MBA, FACP
APP/Nurse/Navigator Survivorship Care Planning: Best Practices

Rick McDonough, MD

Smitha Pabbathi, MD

Karen Stephenson, DNP, MBA, APRN, OCN

Administrator Challenges with Specialized Testing Rise Marie Cleland
Administrator Prior Authorization Burdens

Rise Marie Cleland

Andrew Hertler, MD, FACP

© 2021 FLASCO | Premium Website Design by The HDG